Cara Therapeutics Inc

NASDAQ:CARAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Contact Information

Headquarters

400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901

Phone

203-406-3700

Fax

203-567-1510

Executives

Independent Chairman of the Board

Martin Vogelbaum

President, Chief Executive Officer, Director

Christopher Posner

Chief Financial Officer

Ryan Maynard

Chief Compliance Officer, General Counsel, Secretary

Scott Terrillion

Director

Helen Boudreau